Mar. Drugs 2013, 11(7), 2293-2313; doi:10.3390/md11072293
Review

Strategies for the Development of Conotoxins as New Therapeutic Leads

email, email and * email
Received: 14 April 2013; in revised form: 27 May 2013 / Accepted: 6 June 2013 / Published: 28 June 2013
(This article belongs to the Special Issue Marine Peptides and Their Mimetics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins.
Keywords: peptide toxin; peptidomimetic; ion channel; pain; cone snail
PDF Full-text Download PDF Full-Text [659 KB, uploaded 28 June 2013 11:20 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Brady, R.M.; Baell, J.B.; Norton, R.S. Strategies for the Development of Conotoxins as New Therapeutic Leads. Mar. Drugs 2013, 11, 2293-2313.

AMA Style

Brady RM, Baell JB, Norton RS. Strategies for the Development of Conotoxins as New Therapeutic Leads. Marine Drugs. 2013; 11(7):2293-2313.

Chicago/Turabian Style

Brady, Ryan M.; Baell, Jonathan B.; Norton, Raymond S. 2013. "Strategies for the Development of Conotoxins as New Therapeutic Leads." Mar. Drugs 11, no. 7: 2293-2313.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert